Intercept Pharmaceuticals Inc (ICPT)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

10 HUDSON YARDS, 37TH FLOOR NEW YORK, NY 10001

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea.

Data as of 2021-04-11 07:27:01 -0400
Market Cap731.956 Million Shares Outstanding33.016 Million Avg 30-day Volume1.015 Million
P/E Ratio-2.66282 Dividend Yield EPS-8.34
Price/Sales2.34 Debt to Equity-3.48 EBITDA-213.492 Million
Price to Book Value-4.39 Forward PE-4.24 Enterprise Value822.871 Million
Total Cash469.667 Million Current Debt179.076 Million Gross Profit307.368 Million
BETA0.97745 52-week High/Low95.98 / 18.15 Next Earnings Date2021-05-10 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from ICPT instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 2 -100.0% 2 (0.12%) 6 (0.37%) -66.67%
Funds Holding: 172 176 -2.27% 54 (3.25%) 54 (3.36%) 0.0%
13F shares: 26.706 Million 28.225 Million -5.38% 5.281 Million 6.831 Million -22.68%
% Ownership 80.9457 85.5495 -5.38% 16.0079 20.7043 -22.68%
New Positions: 34 33 3.03% 15 13 15.38%
Increased Positions 57 54 5.56% 18 20 -10.0%
Closed Positions 37 46 -19.57% 15 15 0.0%
Reduced Positions 51 52 -1.92% 15 14 7.14%
Total Calls 1.378 Million 1.204 Million 14.44% 302.2 Thousand 265.1 Thousand 13.99%
Total Puts 1.906 Million 1.313 Million 45.17% 903 Thousand 799.7 Thousand 12.92%
PUT/CALL Ratio 1.38 1.09 26.61% 2.99 3.02 -0.99%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ICPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ICPT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

237 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DURSO JEROME BENEDICT PRESIDENT & CEO

  • Officer
  • Director
82,142 2021-04-01 9

FORD DAVID A CHIEF HUMAN RESOURCES OFFICER

  • Officer
23,839 2021-04-01 9

WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT

  • Officer
27,341 2021-04-01 10

VENEZIA ROCCO CHIEF ACCOUNTING OFFICER

  • Officer
14,289 2021-04-01 2

ROSA-BJORKESON DAGMAR

  • Director
0 2021-04-01 1

PRUZANSKI MARK

  • Director
600,328 2021-03-31 6

AKKARAJU SRINIVAS

  • Director
663,809 2021-03-10 2

DEFRANCESCO LISA SVP, IR & CORP. AFFAIRS

  • Officer
11,592 2021-02-15 1

RICHARDSON LINDA M EVP & CHIEF COMMERCIAL OFFICER

  • Officer
21,335 2021-02-15 2

CAWKWELL GAIL SVP, MED AFFAIRS, SAFETY & PV

  • Officer
32,872 2021-02-12 6

FREEDBERG JARED GENERAL COUNSEL AND SECRETARY

  • Officer
0 2021-02-01 2

KAPADIA SANDIP CFO AND TREASURER

  • Officer
40,964 2021-01-22 5

CAMPAGNA JASON CHIEF MEDICAL OFFICER

  • Officer
20,531 2021-01-22 7

BALL BRYAN CHIEF QUALITY OFFICER

  • Officer
0 2021-01-11 2

KIM RICHARD J PRESIDENT US COMM & STRAT MKTG

  • Officer
19,770 2020-12-31 3

SULLIVAN RYAN T GENERAL COUNSEL AND SECRETARY

  • Officer
24,708 2020-11-13 3

GENEXTRA S.P.A.

4,000,000 2020-08-13 2

FUNDARO PAOLO

4,021,028 2020-08-13 3

MICHELI FRANCESCO

4,000,000 2020-08-13 2

BRIGHT LISA PRESIDENT, INTERNATIONAL

  • Officer
22,012 2020-07-01 1

SBLENDORIO GLENN

  • Director
8,681 2020-05-28 1

BENATTI LUCA

  • Director
10,721 2020-05-28 1

WELCH DANIEL G

  • Director
8,060 2020-05-28 1

SANTINI GINO

  • Director
8,879 2020-05-28 1

GOTTESDIENER KEITH MICHAEL

  • Director
9,953 2020-05-28 1

BRADBURY DANIEL

  • Director
16,594 2020-05-28 1

MILLER-RICH NANCY

  • Director
7,538 2020-05-28 1

SHAPIRO DAVID CHIEF MEDICAL OFFICER

  • Officer
39,499 2019-05-01 0

BRIGHT LISA PRESIDENT, INTERNATIONAL

BRIGHT LISA PRESIDENT, INTERNATIONAL

  • Officer
18,807 2019-01-07 1

MCMINN RACHEL CHIEF STRATEGY OFFICER

  • Officer
16,875 2017-10-02 0

DUNCAN BARBARA GAYLE CHIEF ACCOUNTING OFFICER

  • Officer
30,661 2016-10-03 0

ADORINI LUCIANO SEE REMARKS

  • Officer
No longer subject to file 2016-02-01 0

VEITINGER KLAUS R DR

  • Director
2,816 2015-11-24 0

SILVERSTEIN JONATHAN

  • Director
1,121,583 2015-11-24 0

WILLIAMS NICOLE

  • Director
962 2015-11-20 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • Director
1,120,609 2015-07-17 0

REGAN DANIEL PAUL CHIEF COMMERCIAL OFFICER

  • Officer
1,264 2015-01-30 0

PATEL SANJ K

  • Director
452 2014-07-17 0

TALLARIGO LORENZO

  • Director
0 2014-07-07 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FORD DAVID A - Officer CHIEF HUMAN RESOURCES OFFICER

2021-04-05 19:02:55 -0400 2021-04-01 F 92 $24.28 d 23,839 direct -1.2325 0.0 1 -1.2325 2

VENEZIA ROCCO - Officer CHIEF ACCOUNTING OFFICER

2021-04-05 19:03:08 -0400 2021-04-01 F 29 $24.28 d 14,289 direct -1.2325 0.0 1 -1.2325 2

DURSO JEROME BENEDICT - Director - Officer PRESIDENT & CEO

2021-04-05 19:02:27 -0400 2021-04-01 F 289 $24.28 d 82,142 direct -1.2325 0.0 1 -1.2325 2

WEYER CHRISTIAN - Officer EVP, RESEARCH & DEVELOPMENT

2021-04-05 19:03:30 -0400 2021-04-01 F 46 $24.28 d 27,341 direct -1.2325 0.0 1 -1.2325 2

PRUZANSKI MARK - Director

2021-04-01 19:00:48 -0400 2021-03-31 F 3,658 $23.08 d 500,328 direct -3.9592 0.0 1 -3.9592 2

PRUZANSKI MARK - Director

2021-04-01 19:00:48 -0400 2021-03-31 A 6,136 $23.08 a 503,986 direct -3.9592 0.0 1 -3.9592 2

AKKARAJU SRINIVAS - Director see footnote

2021-03-12 19:51:29 -0500 2021-03-12 P 147,000 $21.29 a 640,688 indirect -3.9633 -1.7522 0.0 1 -7.3842 4

AKKARAJU SRINIVAS - Director see footnote

2021-03-12 19:51:29 -0500 2021-03-10 P 16,559 $21.55 a 493,688 indirect -3.9633 -1.7522 0.0 1 -7.3842 4

AKKARAJU SRINIVAS - Director see footnote

2021-03-12 19:51:29 -0500 2021-03-10 P 73,441 $20.83 a 477,129 indirect -3.9633 -1.7522 0.0 1 -7.3842 4

WEYER CHRISTIAN - Officer EVP, RESEARCH & DEVELOPMENT

2021-03-02 19:00:51 -0500 2021-02-27 F 357 $21.66 d 27,387 direct -6.8434 -2.0723 7.1325 5 -6.8434 2

PRUZANSKI MARK - Director

2021-03-02 19:01:55 -0500 2021-02-26 A 6,138 $21.66 a 500,591 direct -6.8434 -2.0723 7.1325 5 -6.8434 2

PRUZANSKI MARK - Director

2021-03-02 19:01:55 -0500 2021-02-26 F 2,741 $21.66 d 497,850 direct -6.8434 -2.0723 7.1325 5 -6.8434 2

DURSO JEROME BENEDICT - Director - Officer PRESIDENT & CEO

2021-02-25 19:01:04 -0500 2021-02-23 F 319 $28.12 d 82,431 direct 0.0923 -4.6168 0.0923 2 -10.7572 5

RICHARDSON LINDA M - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-02-17 19:04:36 -0500 2021-02-15 A 8,500 a 8,500 direct

RICHARDSON LINDA M - Officer EVP & CHIEF COMMERCIAL OFFICER

2021-02-17 19:04:36 -0500 2021-02-15 A 5,531 a 26,866 direct 0.0321 -26.0904 -22.1296 0.0321 2 -38.0051 11

CAWKWELL GAIL - Officer SVP, MED AFFAIRS, SAFETY & PV

2021-02-17 19:00:41 -0500 2021-02-12 F 319 $31.32 d 32,872 direct 0.0321 -26.0904 -22.1296 0.0321 2 -38.0051 11

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 22:15:03 UTC -0.2202 0.2802 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 21:45:03 UTC -0.2188 0.2788 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 21:15:02 UTC -0.2188 0.2788 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 20:45:03 UTC -0.1962 0.2562 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 20:15:03 UTC -0.1962 0.2562 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 19:45:03 UTC -0.1962 0.2562 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 19:15:03 UTC -0.1962 0.2562 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 18:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 18:15:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 17:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 17:15:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 16:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 16:15:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 15:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 15:15:02 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 14:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 14:15:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 13:45:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 13:15:03 UTC -0.19 0.25 80000
INTERCEPT PHARMACEUTICALS IN ICPT 2021-04-12 12:45:03 UTC -0.19 0.25 80000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AQR Funds- AQR Multi-Strategy Alternative Fund ICPT -9.0 shares, $-373.14 2020-09-30 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund ICPT -8673.0 shares, $-307978.23 2020-11-30 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio ICPT -1051.0 shares, $-25959.7 2020-12-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund ICPT -8028.0 shares, $-198291.6 2020-12-31 N-PORT
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund ICPT -1113.0 shares, $-27491.1 2020-12-31 N-PORT
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund ICPT -26500.0 shares, $-933860.0 2021-01-31 N-PORT

Elevate your investments